Natural variants of human papillomavirus (HPV) are classified into lineages and sublineages based upon whole-genome sequence, but the impact of diversity on protein function is unclear. We investigated the susceptibility of 3-8 representative pseudovirus variants of HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58 to neutralization by nonavalent vaccine (Gardasil®9) sera. Many variants demonstrated significant differences in neutralization sensitivity from their consensus A/A1 variant but these were of a low magnitude. HPV52 D and HPV58 C variants exhibited >4-fold reduced sensitivities compared to their consensus A/A1 variant and should be considered distinct serotypes with respect to nonavalent vaccine-induced immunity.
Bibliographical noteFunding Information:
Financial support. This work was supported by Public Health England; the National Cancer Institute, National Institutes of Health (contract number HHSN261200800001E); and by the Bill and Melinda Gates Foundation to develop and distribute qualified standardized reagents for human papillomavirus research as a service to be made available to the extramural research community.
© 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
- human papillomavirus